Development and validation of a prognostic signature for malignant pleural mesothelioma by Zhou, J.-G. et al.
ORIGINAL RESEARCH
published: 15 February 2019
doi: 10.3389/fonc.2019.00078
Frontiers in Oncology | www.frontiersin.org 1 February 2019 | Volume 9 | Article 78
Edited by:
Marco Lucchi,
University of Pisa, Italy
Reviewed by:
Steven G. Gray,








†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology
Received: 24 August 2018
Accepted: 29 January 2019
Published: 15 February 2019
Citation:
Zhou J-G, Zhong H, Zhang J, Jin S-H,
Roudi R and Ma H (2019)
Development and Validation of a




Development and Validation of a
Prognostic Signature for Malignant
Pleural Mesothelioma
Jian-Guo Zhou 1*†, Hua Zhong 2†, Juan Zhang 3, Su-Han Jin 4, Raheleh Roudi 5 and Hu Ma 1*
1Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi, China, 2College of Life Sciences, Wuhan
University, Wuhan, China, 3Department of Bioinformatics, School of Basic Medical Sciences, Fujian Medical University,
Fuzhou, China, 4Department of Orthodontics, Affiliated Stemmatological Hospital of Zunyi Medical University, Zunyi, China,
5Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
Introduction:Dysregulated genes play a critical role in the development and progression
of cancer, suggesting their potential as novel independent biomarkers for cancer
diagnosis and prognosis. Prognostic model-based gene expression profiles are not
widely utilized in clinical medicine. We investigated the prognostic significance of an
expression profile-based gene signature for outcome prediction in patients withmalignant
pleural mesothelioma (MPM).
Methods: The gene expression profiles of a large cohort of patients with MPM were
obtained and analyzed by repurposing publicly available microarray data. A gene-
based risk score model was developed with the training dataset and then validated
with the TCGA-MESO (mesothelioma) dataset. The time-dependent receiver operating
characteristic (ROC) curve was used to evaluate the prognostic performance of
survival prediction. The biological function of the prognostic genes was predicted using
bioinformatics analysis.
Results: Three genes in the training dataset (GSE2549) were identified as significantly
associated with the overall survival (OS) of patients with MPM and were combined to
develop a three-gene prognostic signature to stratify patients into low-risk and high-risk
groups. The MPM patients of the training dataset in the low-risk group exhibited longer
OS than those in the high-risk group (HR = 0.25, 95% CI = 0.11–0.56, P < 0.001).
Similar prognostic values for the three-gene signature were observed in the validated
TCGA-MESO cohort (HR = 0.53 95% CI = 0.33–0.85, P = 0.008). ROC analysis also
demonstrated the good performance in predicting 3-year OS in the GEO and TCGA
cohorts (KM-AUC for GEO = 0.989, KM-AUC for TCGA = 0.618). The C-statistic for
the 3-gene model was 0.761. Validation with TCGA-MESO confirmed the model’s ability
to discriminate between risk groups in an alternative data set with fair performance (C-
statistic: 0.68). Functional enrichment analysis suggested that these three genes may be
involved in genetic and epigenetic events with known links to MPM.
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Conclusions: This study has identified and validated a novel 3-gene model to reliably
discriminate patients at high and low risk of death in unselected populations of patients
with MPM. Further larger, prospective multi-institutional cohort studies are necessary to
validate this model.
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BACKGROUND
Malignant pleural mesothelioma (MPM) is a rare cancer
worldwide (1). However, MPM is a highly aggressive cancer
appearing from the mesothelial lining of the thoracic cavities.
Because most patients have advanced stage at presentation,
MPM is difficult to treat. With the median survival of
patients with MPM <1 year and their 5-year survival rate
<5% (1–3), MPM is one of the most aggressive cancers,
although some patients exhibited a good response to
chemotherapy, radiotherapy or multimodal therapy. It is
therefore important to identify the prognostic value of novel
markers that can aid in selecting patients who will benefit from
such treatments.
Dysregulated genes play a critical role in the development
and progression of MPM, suggesting their potential as novel
independent biomarkers for cancer diagnosis and prognosis (4).
In recent decades, a large number of genes and microRNAs
were identified as prognostic biomarker in patients with MPM
(5, 6). BRCA1-associated protein 1 (BAP1) was the first gene
evaluated as an independent prognostic parameter for MPM (7).
Furthermore, an increasing number of genes, such as circulating
fibrinogen (8), Ki67 (9), CD74 (10), Wnt7A (11), EMX2 (12),
and SOM (13), were verified to be prognostic biomarkers in
patients with MPM. Other series of studies have detected the
microRNA content of their cell lines and tumor tissues. The
loss of miR-31 from MPM tumors promotes chemosensitivity
and may be a marker indicating susceptibility to chemotherapy
(14). Although The Cancer Genome Atlas (TCGA) database
does not contain normal samples, Meerang and his colleagues
have authenticated a 6-microRNA model to accurately predict
the prolonged survival for MPM patients (15). While several
prognostic factors have been proposed, only a few have been
independently validated.
In the present study, we integrate the gene expression profiles
and matched clinical information from a GEO cohort including
the patients with MPM, we detected three prognostic coding
genes as biomarkers associated with the overall survival (OS)
of patients with MPM. This established 3-gene prognostic
risk model can effectively predict OS, and the significant
prognostic power of this model was further validated in the
TCGA-MESO cohort.
Abbreviations: MPM, malignant pleural mesothelioma; GEO, Gene Expression
Omnibus; TCGA, The Cancer Genome Atlas; AUC, area under the ROC curve;
ROC, receiver operating characteristic; HR, Hazard ratio; CI, confidence interval;
OS, overall survival; KM, Kaplan-Meier, NNE, nearest neighbor estimation
method, GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes;
GSEA, gene set enrichment analysis.
EVIDENCE BEFORE THIS STUDY
PubMed was searched for articles relating to
prognostic signatures in MPM using the search
expression “prognostic [Title/Abstract] AND
signature [Title/Abstract] AND [(Malignant pleural
mesothelioma[Title/Abstract]) OR (MPM[Title/Abstract])
OR (mesothelioma[Title/Abstract])]” with no filters. This search
returned 6 articles, which were reviewed. One was a review
article (5), 3 focused on microRNA signatures (16–18), another
evaluated a proinflammatory prognostic signature (19), and
the other identified a death-from-cancer signature (20). The
lack of relevant search results indicated that no gene prognostic
signatures for MPM have been developed.
Data Processing and Computational
Analysis
The 49 RNA expression profiles included data from MPM
surgical specimens (n = 40), normal pleura specimens (n
= 5), and normal lung specimens (n = 4) in GSE2549
(Affymetrix Human Genome U133A Array) (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc$=$GSE2549) (21). The raw
data in the dataset were annotated to obtain the gene expression
levels, and the average expression values of probes were
considered the expression values of the corresponding genes.
Next, the expression values of the genes were subjected to log2
transformation and normalization using the Limma package
in R language. The data for 84 RNA expression profiles (level
FIGURE 1 | Prognostic gene analysis and signature generation pipeline.
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3), including data from 84 tumor tissues, were downloaded
from TCGA. This study met the publication guidelines
provided by TCGA (http://cancergenome.nih.gov/publications/
publicationguidelines). According to TCGA guidelines, we chose
the RNA-Seq count quantified by RSEM for the RNA expression
profiles (22). The differentially expressed genes were selected
according to P-value ≤ 0.05 and false discovery rate (FDR)
≤ 0.05 (23). The overall workflow of this study was shown
in Figure 1.
Identification of Prognosis-Related Genes
One of 40 MPM samples did not have complete survival data,
and we removed this case. Ultimately, 39 MPM samples and
nine normal samples were included for the identification of
differentially expressed genes. GSE2549 was used as the training
set (39 samples), and TCGA-MESO was used as the validation
set (84 samples). To discover the feasibility and reliability of
a prognostic signature for MPM, univariate Cox proportional
hazards regression analysis was applied to identify OS-related
RNAs from differentially expressed RNAs (24). Then, a robust
likelihood-based survival model was utilized to further identify
prognosis-related RNAs by the R package survival (25). We
calculated the Akaike information criterion (AIC), which is an
estimator of the relative quality of statistical models for a given
set of data, and chose the optimal model with the smallest AIC. A
risk score was calculated by considering the gene expression and
the correlation coefficient. Moreover, all patients were divided
into different groups (high-risk group or low-risk group) based
on the median of the risk score. Hazard ratios (HRs) and 95%
confident intervals (95% CIs) were calculated. Kaplan-Meier
analysis with the log-rank test for difference was performed by the
R package survival (25). Heatmaps were generated in TreeView
with z-score normalization within each row (gene). The time-
dependent receiver operating characteristic (ROC) curve was
used to appraise the prognostic performance of the risk model
for survival prediction, and the area under the ROC curve (AUC)
values were calculated with the package survivalROC (version
1.0.3) (26–28). The concordance statistic (C-statistic) was used
to measure the goodness of fit of the prognostic model (29). All
statistical tests were two-sided, P-value ≤ 0.05 was considered
statistically significant. All of data were processed and analyzed
by R (version 3.5.0).
Functional Enrichment Analysis
The enriched results were reported with Gene Ontology (GO)
terms and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway categories using the functional annotation clustering
and functional annotation chart options (30, 31). The GO terms
and KEGG pathways with a P-value of < 0.05 were considered
significantly enriched function annotations.
RESULTS
Identification of Prognostic Genes
To comprehensively analyze the genomic prognostic associations
in MPM, we developed an analysis pipeline (Figure 1). GSE2549
as training set (39 samples) and TCGA-MESO as validation
set (84 samples). In GSE2549 cohort, we analyzed ∼12,432
genes with normalization. Univariate Cox proportional hazards
regression analysis showed that 22 genes were statistically
significantly correlated with OS while a P-value of≤ 0.01, though
genes with lower statistical significance may be important as well
(Table S1, available online). An FDR threshold of ≤ 0.05 further
refined the candidate gene list to 8 genes (Table 1) to ensure
proper performance of algorithm in signature generation.
Development and Validation of the
Prognostic Signature
The 8 genes were used for prognostic signature building using
forward conditional stepwise regression with multivariable Cox
analysis in the training cohort (GSE2549). This procedure
selected a prognostic model containing three genes: LSM6
TABLE 2 | Survival-associated gene signature screening using forward selection.
Model AIC
CDC20 + LSM6 + GZMB + NCAPG + HJURP + SHCBP1 +
KIF18B + RACGAP1
169.04
CDC20 + LSM6 + GZMB + HJURP + SHCBP1 + KIF18B +
RACGAP1
167.21
LSM6 + GZMB + HJURP + SHCBP1 + KIF18B + RACGAP1 165.4
LSM6 + GZMB + HJURP + SHCBP1 + KIF18B 164.05
LSM6 + GZMB + HJURP + SHCBP1 162.58
LSM6 + GZMB + HJURP 161.29
TABLE 1 | Survival-associated gene signature screening using univariate Cox analysis.
Gene ID Symbol HR z_score P-value FDR
64151 NCAPG 1.027254347 4.24991572 2.14E−05 0.025263053
3002 GZMB 1.019847944 4.218060896 2.46E−05 0.025263053
55355 HJURP 1.026508209 4.191920631 2.77E−05 0.025263053
146909 KIF18B 1.019149889 4.088171084 4.35E−05 0.029782941
991 CDC20 1.018569099 3.989784332 6.61E−05 0.033533683
79801 SHCBP1 1.028501087 3.952872889 7.72E−05 0.033533683
29127 RACGAP1 1.018274577 3.91248921 9.13E−05 0.033533683
11157 LSM6 1.025921361 3.895717234 9.79E−05 0.033533683
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FIGURE 2 | Three-gene prognostic signature biomarker performance in the training cohort. (A) The risk scores for all patients in the GSE2549 dataset are plotted in
ascending order and marked as low risk (bottle green) or high risk (red), as distinguished by the threshold (vertical dashed line). (B) Survival status for three prognostic
genes in 39 patients of the GSE2549 dataset. Dark red indicates dead, and dark blue indicates alive. (C) Heatmap of the three prognostic genes in the GSE2549
dataset with differential expression between the high- and low-risk groups. Dark red indicates higher expression, and light yellow indicates lower expression. (D)
Kaplan-Meier estimates for the overall survival of patients in the GSE2549 dataset stratified by the three-gene prognostic signature into high and low risk with the
log-rank hazard ratio (HR), 95% confidence interval (CI), P-value, and median survival (days).
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FIGURE 3 | Three-gene prognostic signature biomarker performance in the validation cohort. (A) The risk scores for all patients in the TCGA cohort are plotted in
ascending order and marked as low risk (bottle green) or high risk (red), as distinguished by the threshold (vertical imaginary line). (B) Survival status for the three
prognostic genes in the TCGA cohort. Dark red indicates dead, and Dodger blue indicates alive. (C) Heatmap of the three prognostic genes in the TCGA cohort that
were differentially expressed between the high- and low-risk groups. Dark red indicates higher expression, and light yellow indicates lower expression. (D)
Kaplan-Meier estimates for the overall survival of patients in the TCGA cohort stratified by the three-gene prognostic signature into high and low risk with the log-rank
hazard ratio (HR), 95% confidence interval (CI), P-value, and median survival (days).
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(ENSG00000164167), GZMB (ENSG00000164167), and HJURP
(ENSG00000123485) (Tables 2, 3). A risk score was constructed
with the regression coefficients from this model, and a threshold
was chosen manually at the median (Figure 2A). Risk score
= (0.0133323 × expression value of LSM6) + (0.01643 ×
expression value of GZMB) + (0.020926 × expression value
of HJURP). Low-risk patients, as defined by the three-gene-
signature-based risk score, had statistically significantly better OS
(median 622.5 days vs. 243 days, HR= 0.25, 95% CI= 0.11–0.56,
P < 0.001) in the GSE2549 cohort (Figure 2).
Furthermore, in order to examine the robustness and practical
application of the three-gene risk score model, we validated
the prognostic power of this 3-gene signature using the mRNA
expression values and survival information of MPM patients in
another independent external dataset (TCGA-MESO). As shown
in Figure 3, the 3-gene-signature-based risk score model could
effectively predict OS in patients with MPM in the TCGA-MESO
dataset. All 84 patients in the TCGA-MESO dataset were divided
into a low-risk group (n = 42) and a high-risk group (n =
42) with significantly different OS according to the same risk
score cutoff point obtained from the training dataset (median
512.5 days vs. 347 days, HR = 0.53, 95% CI = 0.33–0.85,
P = 0.008).
Development and Validation of a
Prognostic Signature Based on Published
Factors
Based on the literature regarding prognostic markers in
MPM, we found 19 genes as independent prognostic factors
(the completed dataset for COX was shown in Table S2,
available online). According to the protocol, this procedure
selected a prognostic model containing nine genes: WT1
(ENSG00000184937), PTEN (ENSG00000171862), PGF
(ENSG00000119630), PDPN (ENSG00000162493), HTRA1
(ENSG00000166033), EMX2 (ENSG00000170370), EGFR
(ENSG00000146648), DPP4 (ENSG00000197635), and
CALB2 (ENSG00000172137). Risk score = (0.0133323 ×
expression value of LSM6) + (0.01643 × expression value
of GZMB) + (0.020926 × expression value of HJURP).
Low-risk patients, as defined by the three-gene-signature-
based risk score, had statistically significantly better OS
FIGURE 5 | ROC analysis of the sensitivity and specificity for survival
prediction of the three-gene and nine-gene prognostic models. The
time-dependent ROC curves for overall survival were compared to evaluate
the prognostic performance for survival prediction at 3 years in patients with
MPM. MPM, malignant pleural mesothelioma; ROC curve, receiver operating
characteristic curve; AUC, area under the curve; GEO, Gene Expression
Omnibus; TCGA, The Cancer Genome Atlas; KM, Kaplan-Meier; NNE,
Nearest neighbor estimation method.
FIGURE 4 | Nine-gene prognostic signature biomarker performance with the training and validation cohorts. (A) Kaplan-Meier estimates for the overall survival of
patients in the GEO cohort stratified by the nine-gene prognostic signature into high and low risk with the log-rank hazard ratio (HR), 95% confidence interval (CI),
P-value, and median survival (days). (B) Kaplan-Meier estimates for the overall survival of patients in the TCGA cohort stratified by the nine-gene prognostic signature
into high and low risk with the log-rank hazard ratio (HR), 95% confidence interval (CI), P-value, and median survival (days).
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(median 622.5 days vs. 243 days, HR = 0.36, 95% CI =
0.17–0.77, P = 0.020) in the GSE2549 cohort (Figure 4A).
However, there was no survival difference between the
two groups in the TCGA-MESO dataset (median 470
days vs. 458 days, HR= 0.84, 95% CI = 0.53–1.34,
P = 0.732) (Figure 4B).
Performance Comparison by
Time-Dependent ROC Curve Analysis
We performed time-dependent ROC curve analysis to compare
the sensitivity and specificity of survival prediction between
the 3-gene-signature-based risk score model and the 9-gene
prognostic model with the GSE2549 dataset and the TCGA-
MESO dataset. The AUC value was obtained from ROC analysis
and was compared between these two predictive models. In
the GSE2549 and TCGA-MESO datasets, the 3-gene-signature-
based risk score model achieved KM-AUC values of 0.989
and 0.618, respectively, and were higher than those (KM-
AUC = 0.921 and 0.457, respectively) derived from 9-gene
prognostic model (Figure 5). The C-statistic for the 3-gene
model was 0.761. Validation with TCGA-MESO confirmed
the model’s ability to discriminate between risk groups in
an alternative data set with fair performance (C-statistic:
0.68). These results indicate that the predictive ability of
the 3-gene-signature-based risk score model was better than





To explore the functional implication of the prognostic
genes in MPM tumorigenesis and development, we performed
bioinformatics analysis to predict gene functions. The functional
enrichment assay revealed that 61 GO terms and 10 pathways
were involved (P < 0.05). The result of GO enrichment
analysis showed that the genes are involved in multiple
biological processes, such as cell adhesion molecule binding,
cadherin binding, and unfolded protein binding (Figure 6, and
Table S3, available online). KEGG analysis showed enrichment
in several cancer-related pathways, including some well-
known pathways such as the cell cycle, DNA replication, and
the adipocytokine signaling pathway (Figure 7, and Table S4,
available online).
DISCUSSION
In the past years, great progress has been made in our
understanding of the initiation and progression of MPM.
However, the clinical outcome of patients with MPM still
remains highly heterogeneous. Numerous studies devoted to
differentially expressed genes in MPM by microarray. Gordon
et al used the expression profiling data to accurately distinguish
between MPM and adenocarcinoma, however, this method
did serve as the prognostic markers (32). The first research
FIGURE 6 | Gene ontology analyses of the prognostic genes according to their biological process, cellular component and molecular function.
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FIGURE 7 | KEGG analyses of the pathways of the prognosis-related genes.
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TABLE 3 | Details of the 3-gene model.
Gene coef exp(coef) se(coef) exp(-coef) L U z-value P
LSM6 0.0133323 1.013 0.007 0.9868 0.9995 1.027 1.893 0.0583
GZMB 0.01643 1.017 0.005 0.9837 1.0061 1.027 3.126 0.002
HJURP 0.020926 1.021 0.007 0.9793 1.0077 1.008 3.105 0.002
to detect the prognotic model for MPM by chip, but the
cross-validation only included 29 patients with mesothelioma
(33). In subsequent studies they found that gene ratios in
translating gene expression data could predict the outcome in
MPM (34, 35). Although, the first time to extract sufficient
RNA in Fine-Needle Aspiration biopsies, and explore the
prognostic test in MPM, however, did not report the survival
(36). In an effort to increase clinical tools and the biological
understanding of MPM, we present the first gene prognostic
signature to distinguish normal samples from tumor samples.
Using a GEO cohort subset, we found 22 genes with a
statistically significant association with prognosis. Prognostic
model training in this subset selected a three-gene signature. The
three-gene prognosis signature was validated to be statistically
significantly associated with OS in the remaining TCGA-
MESO cohort. Compared with a 9-gene model developed
using genes identified in the literature, this model has better
predictive ability. Thus, our three-gene prognostic signature
provides biological insights and has potential for rapid
incorporation into clinical detection programs for tailoringMPM
management strategies.
We also note that the high-risk group identified in our
analysis displayed enrichment for genes associated with cell
adhesion molecule binding, cadherin binding, and so on.
Adhesion (37, 38) and cadherin (39) are classical cell-to-cell
adhesion molecules with a homeostatic function in several
normal tissues; however, dysregulation of these molecules
might be associated with a more aggressive cancer cell
phenotype, leading to epithelial-mesenchymal transition (EMT),
invasion and metastasis and thus influencing the OS. These
prognostic genes and their related pathways have potential
for applications in the development of cancer therapy, mainly
for MPM. Clinical integration of the three-gene signature
needs to be tested directly but appears promising from these
initial results.
Though the three-gene signature is promising, there
are limitations for this initial work. This model included
the TCGA-MESO dataset as a validation cohort, but this
dataset lacks patient samples. Therefore, these findings
must be validated in a prospective study with independent
patient samples.
The clinical data of the two cohorts did not include TNM
stage and other information, which limited our ability to
adjust the predictive power of the signature. The TCGA-MESO
data did not provide normal tissue, so we had to identify
the prognostic signature through the GEO dataset and might
have missing a vital signature, e.g., lncRNA and microRNA.
Given the small sample size, we had a limited number of
patients in the two cohorts for testing the performance of
the signature. The training dataset was an array based U133A
array, whereas the validation cohort was an NGS transcriptomic
sequencing dataset, this might lead to result bias. Microarray
results have some sensitivity to bioinformatics parameters that
may vary among clinical sequencing programs and affect
the performance of the signature, though the validation with
the TCGA-MESO cohort demonstrates some robustness to
pipeline variations.
Here, we have performed the first gene prognostic analysis
in MPM with normal tissues, resulting in an independently
validated three-gene prognostic signature, as well as the
identification of numerous genes with strongly statistically
significant prognostic association for further study. Importantly,
this three-gene prognostic signature performed well in the
GEO and TCGA cohorts. Thus, this prognostic signature could
be a clinically useful tool that is easily incorporated into a
clinical sequencing program to individualize therapy for patients
with MPM.
CONCLUSION
In conclusion, we identified 3 genes associated with the prognosis
of patients with MPM. The predicted target genes and biological
functions of these genes provided further insight into the role
of genes in the development of MPM. This signature has many
potential prognostic and therapeutic implications for MPM
patient management.
AUTHOR CONTRIBUTIONS
J-GZ, S-HJ, and HM conceived, designed, or planned the study.
HZ, JZ, and J-GZ analyzed the data. RR and S-HJ acquired data.
J-GZ, S-HJ, HZ, JZ, and HM helped interpret the results. J-GZ
and HZ provided study materials or patients. J-GZ, S-HJ, and
HM drafted the manuscript. All authors revised and reviewed
this work, and all authors gave their final approval of the
submitted manuscript.
ACKNOWLEDGMENTS
This work was supported by the National Natural Science
Foundation of China (Grant No.81360351, 81660512), the
Special Fund for Traditional Chinese Medicine and Ethnic
Medicine supported by the Administration of Traditional
Frontiers in Oncology | www.frontiersin.org 9 February 2019 | Volume 9 | Article 78
Zhou et al. Prognostic Signature in MPM
Chinese Medicine of Guizhou Province (Grant No.QZYY2017-
113), Projects ZY-201751044 and ZYKY-20173830 supported by
the Zunyi Medical University Training Program of Innovation
and Entrepreneurship for Undergraduates, the Open Project
Program of the Special Key Laboratory of Oral Diseases
Research, Higher Education Institution in Guizhou Province,
and the Master Scientific Research Foundation of Zunyi
Medical University. This research received ESMO ASIA 2018
Merit Award.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fonc.
2019.00078/full#supplementary-material
Table S1 | Survival-associated gene signature.
Table S2 | The completed dataset of 19 genes for COX.
Table S3 | GO enrichment results.
Table S4 | KEGG enrichment results.
REFERENCES
1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med.
(2005) 353:1591–603. doi: 10.1056/NEJMra050152
2. Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D’Amico
TA, et al. Impact of mesothelioma histologic subtype on outcomes in the
Surveillance, Epidemiology, and End Results database. J Surg Res. (2015)
196:23–32. doi: 10.1016/j.jss.2015.01.043
3. Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, et al.
Predicting survival in malignant mesothelioma. Eur Respir J. (2011) 38:1420–
4. doi: 10.1183/09031936.00000811
4. Henderson DW, Reid G, Kao SC, van Zandwijk N, Klebe S, Challenges and
controversies in the diagnosis of malignant mesothelioma: part 2. malignant
mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic
aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol.
(2013) 66:854–61. doi: 10.1136/jclinpath-2013-201609
5. Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni
I, et al. Prognostic and therapeutic implications of microRNA
in malignant pleural mesothelioma. Microrna (2016) 5:12–8.
doi: 10.2174/2211536605666160128151018
6. Mozzoni P, Ampollini L, Goldoni M, Alinovi R, Tiseo M, Gnetti L, et al.
MicroRNA expression in malignant pleural mesothelioma and asbestosis: a
pilot study. Dis Markers (2017) 2017:9645940. doi: 10.1155/2017/9645940
7. Righi L, Duregon E, Vatrano S, Izzo S, Giorcelli J, Rondon-Lagos
M, et al. BRCA1-associated protein 1 (BAP1) immunohistochemical
expression as a diagnostic tool in malignant pleural mesothelioma
classification: a large retrospective study. J Thorac Oncol. (2016) 11:2006–17.
doi: 10.1016/j.jtho.2016.06.020
8. Ghanim B, Hoda MA, Klikovits T, Winter MP, Alimohammadi A, Grusch
M, et al. Circulating fibrinogen is a prognostic and predictive biomarker
in malignant pleural mesothelioma. Br J Cancer (2014) 110:984–90.
doi: 10.1038/bjc.2013.815
9. Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, et al. Ki67
index is an independent prognostic factor in epithelioid but not in non-
epithelioid malignant pleural mesothelioma: a multicenter study. Br J Cancer
(2015) 112:783–92. doi: 10.1038/bjc.2015.9
10. Otterstrom C, Soltermann A, Opitz I, Felley-Bosco E, Weder W, Stahel RA,
et al. CD74: a new prognostic factor for patients with malignant pleural
mesothelioma. Br J Cancer (2014) 110:2040–6. doi: 10.1038/bjc.2014.117
11. Hirata T, Zheng Q, Chen Z, Kinoshita H, Okamoto J, Kratz J, et al. Wnt7A is a
putative prognostic and chemosensitivity marker in human malignant pleural
mesothelioma. Oncol Rep. (2015) 33:2052–60. doi: 10.3892/or.2015.3771
12. Giroux Leprieur E, Hirata T, Mo M, Chen Z, Okamoto J, Clement
G, et al. The homeobox gene EMX2 is a prognostic and predictive
marker in malignant pleural mesothelioma. Lung Cancer (2014) 85:465–71.
doi: 10.1016/j.lungcan.2014.06.018
13. Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, et al. SMO
expression level correlates with overall survival in patients with
malignant pleural mesothelioma. J Exp Clin Cancer Res. (2013) 32:7.
doi: 10.1186/1756-9966-32-7
14. Moody HL, Lind MJ, Maher SG. MicroRNA-31 Regulates chemosensitivity
in malignant pleural mesothelioma. Mol Ther Nucleic Acids (2017) 8:317–29.
doi: 10.1016/j.omtn.2017.07.001
15. Kirschner MB, Cheng YY, Armstrong NJ, Lin RC, Kao SC, Linton A, et al.
MiR-score: a novel 6-microRNA signature that predicts survival outcomes in
patients with malignant pleural mesothelioma. Mol Oncol. (2015) 9:715–26.
doi: 10.1016/j.molonc.2014.11.007
16. Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, et
al. Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts
clinical outcome in patients with unresected malignant pleural mesothelioma.
Oncotarget (2017) 8:68627–40. doi: 10.18632/oncotarget.19800
17. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, et al.
MicroRNA signature of malignant mesothelioma with potential diagnostic
and prognostic implications. Am J Respir Cell Mol Biol. (2010) 42:312–9.
doi: 10.1165/rcmb.2009-0060OC
18. De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, et al.
Deregulation ofmiRNAs inmalignant pleural mesothelioma is associated with
prognosis and suggests an alteration of cell metabolism. Sci Rep. (2017) 7:3140.
doi: 10.1038/s41598-017-02694-0
19. Lafferty-Whyte K, Bilsland A, Cairney CJ, Hanley L, Jamieson NB, Zaffaroni
N, et al. Scoring of senescence signalling in multiple human tumour
gene expression datasets, identification of a correlation between senescence
score and drug toxicity in the NCI60 panel and a pro-inflammatory
signature correlating with survival advantage in peritoneal mesothelioma.
BMC Genomics (2010) 11:532. doi: 10.1186/1471-2164-11-532
20. Glinsky GV, Berezovska O, Glinskii AB.Microarray analysis identifies a death-
from-cancer signature predicting therapy failure in patients with multiple
types of cancer. J Clin Invest. (2005) 115:1503–21. doi: 10.1172/JCI23412
21. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson
JP, et al. Identification of novel candidate oncogenes and tumor suppressors
in malignant pleural mesothelioma using large-scale transcriptional
profiling. Am J Pathol. (2005) 166:1827–40. doi: 10.1016/S0002-9440(10)
62492-3
22. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq
data with or without a reference genome. BMC Bioinform. (2011) 12:323.
doi: 10.1186/1471-2105-12-323
23. Li J, Witten DM, Johnstone IM, Tibshirani R. Normalization, testing, and
false discovery rate estimation for RNA-sequencing data. Biostatistics (Oxford,
England) (2012) 13:523–38. doi: 10.1093/biostatistics/kxr031
24. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers
differential expression analyses for RNA-sequencing and microarray studies.
Nucl Acids Res. (2015) 43:e47. doi: 10.1093/nar/gkv007
25. Terry TL, TherneauM. Survival: Contains the Core Survival Analysis Routines,
Including Definition of Surv objects, Kaplan-Meier and Aalen-Johansen (multi-
state) Curves, Cox Models, and Parametric Accelerated Failure Time Models, R
Package Version 2.42-4. (2018). Available online at: https://cran.r-project.org/
26. P.S.-Patrick Heagerty CJ. Time-Dependent ROC Curve Estimation From
Censored Survival Data, R Package Version 1.0.3, (2018). Available online at:
https://cran.r-project.org
27. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for
censored survival data and a diagnostic marker. Biometrics (2000) 56:337–44.
doi: 10.1111/j.0006-341X.2000.00337.x
28. Blanche P, Dartigues JF, Jacqmingadda H. Estimating and comparing
time-dependent areas under receiver operating characteristic curves for
censored event times with competing risks. Stat Med. (2013) 32:5381–97.
doi: 10.1002/sim.5958
Frontiers in Oncology | www.frontiersin.org 10 February 2019 | Volume 9 | Article 78
Zhou et al. Prognostic Signature in MPM
29. Uno H, Cai T, Pencina MJ, D’Agostino RB, Wei LJ. On the C-statistics
for Evaluating overall adequacy of risk prediction procedures with censored
survival data. Stat Med. (2011) 30:1105–17. doi: 10.1002/sim.4154
30. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for
comparing biological themes among gene clusters. Omics (2012) 16:284–7.
doi: 10.1089/omi.2011.0118
31. Yu G, Wang L-G, Yan G-R, He Q-Y. DOSE: an R/Bioconductor package
for disease ontology semantic and enrichment analysis. Bioinformatics (2015)
31:608–9. doi: 10.1093/bioinformatics/btu684
32. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Ramaswamy S,
et al. Translation of microarray data into clinically relevant cancer diagnostic
tests using gene expression ratios in lung cancer and mesothelioma. Cancer
Res. (2002) 62:4963–7. Available online at: http://cancerres.aacrjournals.org/
content/62/17/4963
33. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Richards
WG, et al. Using gene expression ratios to predict outcome among
patients with mesothelioma. J Natl Cancer Inst. (2003) 95:598–605.
doi: 10.1093/jnci/95.8.598
34. Gordon GJ, Rockwell GN, Godfrey PA, Jensen RV, Glickman JN,
Yeap BY, et al. Validation of genomics-based prognostic tests in
malignant pleural mesothelioma. Clin Cancer Res. (2005) 11:4406–14.
doi: 10.1158/1078-0432.CCR-04-2181
35. Gordon GJ, Dong L, Yeap BY, Richards WG, Glickman JN, Edenfield H, et
al. Four-gene expression ratio test for survival in patients undergoing surgery
for mesothelioma. J Natl Cancer Inst. (2009) 101:678–86. doi: 10.1093/jnci/
djp061
36. De Rienzo A, Dong L, Yeap BY, Jensen RV, Richards WG, Gordon GJ, et al.
Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and
prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. (2011)
17:310–6. doi: 10.1158/1078-0432.CCR-10-0806
37. Ali G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, et
al. Differential expression of extracellular matrix constituents and
cell adhesion molecules between malignant pleural mesothelioma
and mesothelial hyperplasia. J Thorac Oncol. (2013) 8:1389–95.
doi: 10.1097/JTO.0b013e3182a59f45
38. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins,
and the inhibitory potential of heparins. Int J Cell Biol. (2012) 2012:676731.
doi: 10.1155/2012/676731
39. van Roy F, Beyond E-cadherin: roles of other cadherin superfamily members
in cancer. Nat Rev Cancer (2014) 14:121–34. doi: 10.1038/nrc3647
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Zhou, Zhong, Zhang, Jin, Roudi and Ma. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Oncology | www.frontiersin.org 11 February 2019 | Volume 9 | Article 78
